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Nac1 is a POZ-domain transcription factor that is involved in the self-renewal of
embryonic stem cells. It is overexpressed in ovarian serous carcinoma and
targeting the interactions of its POZ domain is a potential therapeutic strategy.
Nac1 lacks a zinc-ﬁnger DNA-binding domain and thereby differs from most
other POZ-domain transcription factors. Here, the crystal structure of the Nac1
POZ domain at 2.1 A˚ resolution is reported. The Nac1 POZ domain crystallized
as a dimer in which the interaction interfaces between subunits resemble those
found in the POZ-zinc ﬁnger transcription factors. The organization of the Nac1
POZ-domain core resembles reported POZ-domain structures, whereas the
C-terminus differs markedly. The C-terminal -helix of the Nac1 POZ domain is
shorter than that observed in most other POZ-domain transcription factors;
variation in the organization of this region may be a general feature of POZ-
domain structures.
1. Introduction
Nac1 is a POZ-domain protein that was originally characterized as a
cocaine-inducible gene product in the nucleus accumbens of rat brain
(Cha et al., 1997). It was initially shown to function in the behavioural
responses to psychostimulants (Mackler et al., 2000), although has
subsequently been implicated in diverse physiological processes.
Nac1 mediates the translocation of the ubiquitin–proteosome (UPS)
complex from the nucleus into neuronal dendritic spines, thereby
regulating proteolysis during synaptic remodelling (Shen et al., 2007).
Nac1 also acts as a transcriptional repressor in both neuronal and
non-neuronal cells (Korutla et al., 2002, 2005; Nakayama et al., 2007);
it interacts with the homeodomain protein Nanog and is thus a central
component of the transcription-factor network that maintains the
pluripotency of embryonic stem cells (Wang et al., 2006). Levels of
Nac1 are elevated in advanced ovarian serous carcinoma and cervical
carcinoma (Nakayama et al., 2006; Yeasmin et al., 2008); in ovarian
cancer, expression is particularly high in recurrent disease and in
effusions and is thought to contribute to the development of resis-
tance to chemotherapy (Davidson et al., 2007; Ishibashi et al., 2008).
Artiﬁcial knock-down of Nac1 resulted in the apoptosis of ovarian
cancer cell lines and rescued their sensitivity to chemotherapy,
suggesting that this protein may be a potential therapeutic target.
POZ (poxvirus and zinc ﬁnger; also known as BTB, bric-a`-brac,
tramtrack and broad complex) domains are protein–protein inter-
action motifs that are found in over 200 human proteins (reviewed in
Stogios et al., 2005). POZ-domain proteins function in a wide range of
biological activities, including transcription, ion-channel gating,
cytoskeletal dynamics and protein degradation via the ubiquitin–
proteasome (UPS) system. Approximately 40 transcription factors
contain N-terminal POZ domains (POZ-TFs); many of these play
roles in development and the deregulation of POZ-TF expression has
been observed in several human cancers (reviewed in Kelly & Daniel,
2006). Most POZ-TFs contain C2H2 zinc-ﬁnger or basic leucine-
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zipper DNA-binding domains; however, Nac1 is distinct and does not
contain any characterized DNA-binding motifs. The mechanism by
which Nac1 interacts with DNA is not known, although target genes
have been identiﬁed by chromatin immunoprecipitation and micro-
array approaches (Kim et al., 2008). POZ domains mediate the homo-
dimerization of POZ-zinc ﬁnger transcription factors and also direct
the formation of higher order oligomers and heteromeric POZ–POZ
complexes; the oligomeric organization of Nac1 has not been char-
acterized. Crystal structures of the POZ domains from the zinc-ﬁnger
proteins PLZF (promyelocytic leukaemia zinc ﬁnger; Ahmad et al.,
1998; Li et al., 1999), BCL6 (B-cell lymphoma 6; Ahmad et al., 2003;
Ghetu et al., 2008; Stead et al., 2008) and LRF (leukaemia/lymphoma-
related factor; Schubot et al., 2006; Stogios et al., 2007) revealed
domain-swapped homodimers that are thought to represent the
biologically active unit. In contrast, the Miz-1 (Myc-interacting zinc-
ﬁnger protein 1) POZ domain crystallized as a tetramer in which two
POZ dimers interact via a -sheet region (Stead et al., 2007); this
tetrameric organization was also observed in solution, suggesting that
this interface may be important in the higher order homo- and
hetero-oligomerization of the POZ-TFs in vivo.
POZ domains interact with non-POZ partners in a highly speciﬁc
manner. The POZ-TF POZ domains recruit transcriptional co-
regulators: for example, BCL6 binds the co-repressors BCoR (BCL6-
interacting co-repressor), SMRT (silencing mediator for retinoid and
thyroid hormone receptors) and NCoR (nuclear receptor co-
repressor), whereas Nac1 recruits CoREST (co-repressor of RE1-
silencing transcription factor, also known as RCoR; Korutla et al.,
2007). The Nac1 POZ domain also interacts with cullin 3, consistent
with its role in the UPS system (Shen et al., 2007). Targeting the
interactions of POZ domains with their transcriptional co-repressors
is a strategy for the treatment of tumours associated with deregulated
POZ-TF expression. Crystal structures of BCL6 in association with
BCoR (Ghetu et al., 2008) and SMRT (Ahmad et al., 2003) peptides
led to the design of inhibitors that interfere with co-repressor
recruitment; these inhibitors induced the apoptosis of diffuse large
B-cell lymphoma (DLBCL) tumour cells that overexpress BCL6 and
are promising therapeutic agents (Parekh et al., 2008). Targeting the
interactions of the Nac1 POZ domain is a potential strategy for the
treatment of ovarian cancer; here, we report the crystal structure of
the Nac1 POZ domain to 2.1 A˚ resolution.
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Figure 1
Structure of the Nac1 POZ domain. (a) Sequence alignment of the Nac1, Miz-1, PLZF, BCL6 and LRF POZ domains. Sequences were aligned using ClustalW. The observed
secondary-structure elements of the Nac1 POZ domain are indicated, with -helices in orange and -sheets in green. The residues of 6 in the Miz-1, PLZF, BCL6 and LRF
POZ domains are shown in pale orange. (b) Ribbon representation of the Nac1 POZ-domain dimer. The position of the F98D mutation is shown with an asterisk. The
secondary-structure elements of chain A are indicated, together with 10 and 50 of chain B.
electronic reprint
2. Materials and methods
2.1. Cloning
A DNA fragment encoding the Nac1 POZ domain (Nac1 residues
2–125) was ampliﬁed by PCR from a human placental cDNA library
and inserted into the expression vector pGEX-6P-1 (GE Healthcare).
The POZ-domain F98D mutant was generated by PCR with Phusion
High-Fidelity DNA polymerase (Finnzymes) using the oligonucleo-
tides ATGAACGTGGGCGACCAGGACCTGCTCATGTACACG-
GCT and GCTCAGCCGGCCCGTGTAGCAGAAGCTGAGGTA-
CTG.
2.2. Protein expression and purification
GST-fusion proteins were expressed in Escherichia coli BL21
(DE3) pLysS. Bacteria were cultured in 2TY at 310 K to an OD600 nm
of 0.8. Expression of recombinant protein was then induced with
0.1 mM IPTG at 289 K for 16 h. Cells were lysed and fusion proteins
were bound to glutathione-Sepharose 4B (GE Healthcare). The
N-terminal GST tag was removed by cleavage with PreScission
protease in 20 mM Tris–HCl, 75 mM NaCl, 5 mM DTT pH 7.5. The
Nac1 POZ domain was further puriﬁed by gel-ﬁltration chromato-
graphy in 20 mM Tris–HCl, 150 mM NaCl, 5 mM DTT, 5% glycerol
pH 8.6 and concentrated to 14 mg ml1 using Amicon centrifugal
concentrators (Millipore).
2.3. Crystallization
Crystals of the Nac1 POZ domain were grown by sitting-drop
vapour diffusion at 291 K by mixing 2 ml protein solution
(14 mg ml1) with 2 ml reservoir solution (6M ammonium nitrate,
0.1M bis-tris propane pH 7.5). Large crystals were typically obtained
after 48 h. Crystals were mounted in a nylon cryoloop (Hampton
Research) and transferred to mother liquor supplemented with 20%
glycerol for 30 s before being ﬂash-frozen in liquid nitrogen.
2.4. Data collection, structure determination and refinement
X-ray diffraction data were collected under a nitrogen-gas stream
at 100 K on beamline I03 at the Diamond Light Source (Didcot,
England). Data reduction was performed using iMOSFLM and
SCALA (Leslie, 1992; Collaborative Computational Project, Number
4, 1994). The structure was solved using the MrBUMP molecular-
replacement pipeline (Keegan &Winn, 2007); theMrBUMP solution
was obtained using a MOLREP-generated search model from the
LRF POZ domain (PDB code 2if5) with Phaser as the molecular-
replacement program (McCoy et al., 2005). A model was built using
ARP/wARP (Perrakis et al., 1999); this was followed by iterative
model building and reﬁnement in Coot (Emsley & Cowtan, 2004) and
REFMAC (Murshudov et al., 1997), including TLS reﬁnement with
three TLS groups per POZ-domain monomer. The stereochemistry
was analysed with PROCHECK (Laskowski et al., 1993) and
MolProbity (Davis et al., 2007) and structure superpositions were
calculated using the SUPERPOSE server (Maiti et al., 2004); the
PDB entries used for superpositions were Miz-1, 2q81; BCL6, 1r28;
PLZF, 1buo; LRF, 2nn2. Images of protein structures were prepared
using PyMOL (DeLano, 2002).
3. Results and discussion
Expression of the wild-type human Nac1 POZ domain in E. coli
produced highly insoluble recombinant protein, even upon attempted
optimization of the expression and puriﬁcation protocols. The Nac1
POZ-domain sequence is 38% identical to that of Miz-1; since
recombinant Miz1 POZ domain is highly soluble, we used the crystal
structure of the Miz1 POZ domain to predict surface residues that
might contribute to the insolubility of Nac1. Mutation of a single
surface hydrophobic residue (F98D; Fig. 1a) enabled the puriﬁcation
of highly soluble recombinant Nac1 POZ domain. This mutation does
not reside near residues that have been implicated either in POZ-
domain oligomerization or in the recruitment of transcriptional co-
repressors. The F98D Nac1 POZ domain was crystallized and the
structure was solved by molecular replacement and reﬁned to
R = 20.63%, Rfree = 24.09% at 2.1 A˚ resolution (Table 1; Fig. 1b).
Nac1 is a distinct POZ-domain transcription factor that does not
contain a characteristic zinc-ﬁnger or basic leucine-zipper DNA-
binding domain. The POZ domains of the individual POZ-zinc ﬁnger
transcription factors have approximately the same degree of homo-
logy to each other as they do to Nac1, suggesting similar timescales of
evolutionary divergence (Fig. 1a). The Nac1 POZ domain crystallized
as a domain-swapped dimer whose interfaces closely resemble those
reported in the POZ domains of the POZ-zinc ﬁnger proteins BCL6,
PLZF and LRF (Fig. 1b). A central hydrophobic interface that buries
1018 A˚2 surface area per monomer is formed by the tight packing of
helices 1, 2 and 3, whereas two -strand interfaces that bury an
additional 947 A˚2 per monomer are formed by the interaction of 1
of one subunit with 5 of the other (Fig. 1b). It is therefore likely that
Nac1 functions biologically as an obligate homodimer in a manner
resembling the POZ-zinc ﬁnger proteins. The organization of
secondary-structure elements in the centre of the Nac1 POZ dimer
(1–5) is the same as in reported POZ structures; compared with
Nac1, the r.m.s.d. values of C-atom positions are 1.62 A˚ for BCL6,
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Table 1
Data-collection and processing statistics.
Values in parentheses are for the highest resolution shell (2.1–2.21 A˚).
Crystal parameters
Space group P41212
Unit-cell parameters (A˚, ) a = 57.69, b = 57.69, c = 172.60,
 = 90,  = 90,  = 90
Data collection
Resolution (A˚) 47.96–2.10 (2.21–2.10)
Wavelength (A˚) 0.9763
Rmerge† (%) 10.3 (50.6)
Rp.i.m.‡ (%) 4.3 (20.5)
hI/(I)i 13.5 (4.0)
No. of unique reﬂections 17928
Multiplicity 6.7 (7.0)
Completeness (%) 100 (100)
Reﬁnement
Resolution (A˚) 2.1
R§ (%) 0.206
Rfree} (%) 0.241
R.m.s.d. stereochemistry††
Bond lengths (A˚) 0.114
Bond angles () 1.294
No. of protein atoms 1857
No. of water molecules 107
Average B factor (A˚2) 18.09
Ramachandran analysis‡‡ (%)
Favoured 96.2
Allowed 100.0
Disallowed 0
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is the integrated
intensity of a given reﬂection and hI(hkl)i is the mean intensity of multiple corresponding
symmetry-related reﬂections. ‡ Rp.i.m. =
P
hkl ½1=ðN  1Þ1=2
P
i jIiðhklÞ  hIðhklÞij=P
hkl
P
i IiðhklÞ, where Ii(hkl) is the integrated intensity of a given reﬂection, hI(hkl)i
is the mean intensity of multiple corresponding symmetry-related reﬂections and N is the
multiplicity of a given reﬂection. § R =
P
hkl

jFoj  jFcj

=
P
hkl jFoj, where Fo and Fc
are the observed and calculated structure factors, respectively. } Rfree is the same as R
but calculated using 5% random data excluded from the reﬁnement. †† R.m.s.d.
stereochemistry is the deviation from ideal values. ‡‡ Ramachandran analysis was
carried out using MolProbity (Davis et al., 2007).
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2.19 A˚ for Miz-1, 2.31 A˚ for PLZF and 2.37 A˚ for LRF. Conserved
residues that constitute a charged pocket in the POZ-TF POZ
domains are also present in Nac1 (Asp31 and Arg45); this region is
thought to be important in transcriptional repression in BCL6 and
PLZF, although the mechanism involved is unknown (Melnick et al.,
2002).
The organization of the C-terminus in the Nac1 POZ domain
differs from that in the reported BCL6, LRF, PLZF and Miz-1 POZ-
domain structures (Fig. 2). The C-terminal residues of the latter POZ
domains form a 12-residue -helix (6) that lies adjacent to 5 on the
outside of the molecule. The corresponding helix in Nac1 is extremely
short and the C-terminal residues are unstructured and diverge away
from 5 to interact with the lower 1–50 sheet. These C-terminal
residues have the highest B factors of the Nac1 POZ-domain crystal
structure in chain B and are disordered in chain A. The residues
corresponding to 6 constitute the least conserved sequences among
the POZ domains of the POZ-TFs and the -helical propensities of
the amino acids in the middle of this region differ greatly. The POZ-
domain 6 helix of the zinc-ﬁnger transcriptional repressor Kaiso
(also known as ZBTB33; PDB code 3fkc) is also extremely short; the
low -helical propensity of the Nac1 and Kaiso residues in the middle
of 6 (glycine in Nac1; glycine and proline in Kaiso) may contribute
to this structural feature. The elongin C proteins contain a POZ
domain that lacks an entire 6 helix; interestingly, the 5 helix of
elongin C is involved in its interaction with the VHL protein in a
manner that would not be compatible with the presence of a POZ-
domain 6 helix in its classical location (Stebbins et al., 1999).
Variation in the length of the C-terminal 6 helix may therefore be a
general feature of POZ domains, although its biological relevance in
the POZ-TFs is unknown.
The recruitment of transcriptional co-repressors to the POZ-TF
POZ domains is highly speciﬁc: for example, BCL6 interacts with
SMRTand BCoR in a mutually exclusive manner, whereas neither of
these co-repressors bind to LRF or Nac1. The residues of SMRTand
BCoR that interact with BCL6 share no sequence homology,
although both bind to the POZ-domain lateral grooves that run
across 1 and up through the dimerization interface. The POZ-
domain dimer recruits two co-repressor molecules symmetrically;
contacts are mediated by residues in 1, l, 2, 3 and 6 of both
POZ subunits and involve the rearrangement of some amino-acid
side chains. Conserved interactions of the BCL6 POZ domain with
SMRT and BCoR involve the main-chain atoms of the co-repressor,
whereas nonconserved interactions are mediated by the side chains.
The most important BCL6 residues that interact with SMRT and
BCoR are notably not conserved in the Nac1 POZ domain: BCL6
residues Gln10, Arg13, Arg24, His116, Arg28 and Tyr58 are replaced
by amino acids of different charge in Nac1, with the equivalent
positions being Glu8, Asn11, Glu22, Glu114, Gln26 and Arg56,
respectively. It will now be relevant to determine the residues that
direct the speciﬁc interactions of the Nac1 POZ domain with the
transcriptional co-repressor CoREST.
This work was funded by Yorkshire Cancer Research and by a
BBSRC studentship to MAS. We thank the staff at the Diamond
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Figure 2
Superposition of POZ-domain structures. (a) Stereo-image of POZ-domain C-atom superposition for Nac1 (red), BCL6 (green), PLZF (yellow) and LRF (blue). The
accession codes of the PDB entries used for superposition were BCL6, 1r28; PLZF, 1buo; LRF, 2nn2. (b) Superposition of the BCL6 (pale green) and Nac1 (pale pink) POZ
domains. The 5 and 6 regions of chain B are highlighted in green (BCL6) and red (Nac1).
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Light Source (Didcot, UK) for assistance during X-ray data collec-
tion.
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